A phase 1/2 study of E6005 in Japanese patients with atopic dermatitis

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221229

Enrollment

Registered

2010-09-03

Start date

2010-09-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatits

Interventions

investigational material(s) Generic name etc : E6005 INN of investigational material : Therapeutic category code : 269 Other agents for epidermis Dosage and Administration for Investigational materia

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Japanese adult male patients with a confirmed diagnosis of atopic dermatitis according to "Guidelines for Management of Atopic Dermatitis" by the Japanese Dermatological Association.

Exclusion criteria

Exclusion criteria: -Patients complicated with eye symptoms (e.g., cataract, retinal detachment), Kaposi varicelliform eruption, and molluscum contagiosum or impetigo contagiosa. -Patients who had or have a severe allergy such as anaphylactic shock, anaphylactic reaction and anaphylactoid reaction or allergy/hypersensitivity to E6005 or any of their excipients.

Design outcomes

Primary

Measure	Time frame
Safety will be assessed by adverse events, clinical laboratory results, vital signs, 12-lead ECGs, and ophthalmology. Pharmacokinetic characteristics of E6005 and metabolite will be evaluated using plasma concentration data.	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026